brimonidine tartrate

Summary

Summary: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Top Publications

  1. Pascual J, Berciano J, Gonzalez A, Grijalba B, Figols J, Pazos A. Autoradiographic demonstration of loss of alpha 2-adrenoceptors in progressive supranuclear palsy: preliminary report. J Neurol Sci. 1993;114:165-9 pubmed
    ..Our data show that abnormalities in the noradrenergic system may justify some clinical features of the PSP clinical picture, this supporting the idea of further study of the clinical effects of noradrenergic drugs in PSP. ..
  2. Nowroozzadeh M. Early flap dislocation with perioperative brimonidine use in laser in situ keratomileusis. J Cataract Refract Surg. 2010;36:368 pubmed publisher
  3. Ziółkowska N, Lewczuk B, Przybylska Gornowicz B. Neuropeptide Y as a presynaptic modulator of norepinephrine release from the sympathetic nerve fibers in the pig pineal gland. Pol J Vet Sci. 2015;18:53-61 pubmed
    ..The results show that NPY is involved in the regulation of NE release from the sympathetic terminals in the pig pineal gland, inhibiting this process via Y2-receptors. ..
  4. Lusthaus J, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf. 2017;16:1071-1078 pubmed publisher
    b>Brimonidine tartrate and brinzolamide eye drops are often used as third and fourth line treatment options to reduce intraocular pressure (IOP) in the management of glaucoma and ocular hypertension...